Pharmaceutical Services
Battle Intensifies in the Obesity Drug Market as Novo Nordisk and Eli Lilly Vie for Dominance
obesity drugs; GLP-1; Wegovy; Zepbound; Novo Nordisk; Eli Lilly; market competition; direct-to-consumer; pharmacy benefit managers; compounders; clinical trials
J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025
Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease
Cigna’s Evernorth unveils 2 new programs aimed at GLP-1s
Programs – Publication Format, Glucagon-Like Peptide 1, Cigna ‘s, GLP-1s, Pharmacy facility, Enhance (action), Pharmaceutical Services
Novo Nordisk Slashes Wegovy Price for Cash-Paying Patients
Wegovy, price cut, Novo Nordisk, NovoCare Pharmacy, obesity treatment, semaglutide, direct-to-patient, cash-paying patients
2025 J.P. Morgan Healthcare Conference: Optimism, Innovation, and Shifting Landscapes
AI in healthcare, outpatient care expansion, pharmaceutical services, regulatory environment, deal activity, digital health, gene editing, Trump administration
FTC Targets Pharmacy Benefit Managers Over Exorbitant Price Hikes on Specialty Generic Drugs
FTC, Pharmacy Benefit Managers, PBM, Specialty Generic Drugs, Price Hikes, Healthcare Costs
FTC Report Reveals Big 3 PBMs Made $7.3 Billion from Excessive Markups on Specialty Generic Drugs
FTC report, Big 3 PBMs, Specialty generic drugs, Price markups, Healthcare costs, Pharmacy benefit managers
Congress Eyes Major PBM Reforms in Year-End Spending Bill
Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.
Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment
Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy
Novo Holdings Receives Unconditional EU Approval for $16.5 Billion Acquisition of Catalent
Novo Holdings, Catalent, European Commission, Acquisition, EU Approval, Pharmaceutical Services